Liomont

What Liomont does

Laboratorios Liomont, S.A. de C.V. is a privately held, 100% Mexican pharmaceutical company founded in 1938 by German chemist Don Martin Lewinberg, headquartered in Mexico City and employing 1,001–5,000 people. The company researches, develops, manufactures, and commercializes a broad portfolio of medications across three product streams: prescription (ethical) pharmaceuticals spanning cardiovascular, analgesic, anti-infective, respiratory, gastrointestinal, dermatological, urological, antidiabetic, oncology, and obesity indications; over-the-counter (libre venta) consumer health brands including Analgen, Conazol, Sensibit, Redustat, and Mucovibrol; and biotechnological products encompassing biosimilars, monoclonal antibodies, and recombinant vaccines. Manufacturing is conducted across three specialized plants: the Cuajimalpa facility (general medicines), the Ocoyoacac plant (sterile injectables — first isolator-based aseptic filling line in Latin America, with an automated robotic distribution center capable of 6,000+ pallets), and the Biotec plant in Cuajimalpa (single-use bioreactor capacity of 12,000 liters/year, ~240,000 annual doses).

Liomont operates a traditional pharmaceutical sales-led go-to-market motion through a field force of medical representatives detailing physicians, specialists, and hospital pharmacy committees across Mexico's public and private healthcare sectors, supplemented by pharmacy and retail distribution for OTC products, government institutional procurement to public hospitals, and export distribution covering 16 international markets in the Americas and Europe. Revenue streams derive from one-time product sales across Rx, OTC, and biopharmaceutical channels, plus licensing/royalty-type arrangements tied to technology transfer partnerships (notably Moderna for mRNA vaccines and AstraZeneca for COVID-19 vaccine manufacturing). The company is ISO 9001 certified and maintains cGMP-compliant operations under COFEPRIS and international regulatory standards.

Strategic positioning centers on Mexico's pharmaceutical self-sufficiency agenda — a thesis reinforced by its 2019 capital investments in advanced manufacturing, its UNAM R&D collaboration for biotech development, and its 2026 selection as Moderna's local manufacturing partner for mRNA vaccines alongside state-owned Birmex and Mexico's Health Ministry.

Name

Liomont

Legal name

Laboratorios Liomont, S.A. de C.V.

Website

https://liomont.com.mx

Company type

Private

Founded year

1938

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Liomont is a 100% Mexican pharmaceutical company founded in 1938 that researches, manufactures, and commercializes prescription drugs, OTC medications, and biopharmaceuticals (biosimilars, monoclonal antibodies, recombinant vaccines) through three specialized manufacturing plants, serving physicians, consumers, public hospitals in Mexico, and 16 international markets across the Americas and Europe.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA)

Keywords

• Pharmaceutical manufacturing
• Prescription medications
• Biopharmaceutical products
• Over-the-counter drugs
• Vaccine manufacturing

Headquarters

HQ city

Mexico City

HQ country

Mexico

HQ region

Latin America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Prescription Pharmaceuticals (Ethical Products): Sale of prescription (ethical) pharmaceutical products through medical representative detailing to healthcare professionals and hospital institutions. Product portfolio covers therapeutic areas including cardiovascular, analgesics, anti-infectives, respiratory, gastrointestinal, dermatological, urological, and antidiabetic medications. Revenue generated through pharmaceutical product sales to hospitals, pharmacies, and distributors.
2. Over-the-Counter (OTC) Products (Libre Venta): Sale of OTC/pharmaceutical products available without prescription, covering categories such as analgesics, cold/flu remedies, dermatologicals, antacids, weight management, and antifungal treatments. Products distributed through pharmacies and retail chains.
3. Biotechnological Products and Vaccines: Manufacturing and sale of biotechnological products including biosimilars, monoclonal antibodies, and recombinant vaccines. This includes partnership-based mRNA vaccine manufacturing (Moderna technology transfer), recombinant protein therapeutics for conditions such as cancer, rheumatoid arthritis, and asthma. Currently expanding capacity with technology transfer agreements.
4. Export Sales: International sales of pharmaceutical products to 16 markets across the Americas and Europe. Includes both prescription and OTC products manufactured in Mexico under international quality standards.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Liomont is a 100% Mexican pharmaceutical company that researches, develops, manufactures, and commercializes a broad portfolio of medicines spanning prescription (Rx) drugs, over-the-counter (OTC) consumer health products, and biotechnological medicines including monoclonal antibodies, biosimilars, and recombinant vaccines. It operates three specialized cGMP-compliant manufacturing plants producing sterile injectables, biotech products, and generic pharmaceuticals, and exports its portfolio to 16 international markets across the Americas and Europe.

Product overview

Liomont is a 100% Mexican pharmaceutical company with 88 years of history, operating three specialized manufacturing plants (Cuajimalpa, Ocoyoacac, and Santa Fe). The company offers a broad portfolio spanning prescription drugs, over-the-counter (OTC) medications, and biopharmaceutical products. Prescription products include analgesics/anti-inflammatories (DAFLOXEN, ANALGEN, SUPRADOL), anti-infectives (Cicloferon, Candiflux, Ceftrianol), cardiovascular medications (LODESTAR, CODEGREGAN, XARABAN), dermatologicals (Locoid, Conazol), gastroenterologicals (INHIBITRON, PRAZOLAN), respiratory drugs (MUCOVIBROL, Sensibit), urologicals (BOLT 36, CONTINENTAL), antiobesity (REDUSTAT, SLENDER), antidiabetics (GLITACAR-1), and osteoporosis treatments (FOSFONAT). OTC products include Analgen, Cicloferon, Candiflux, REDUSTAT, Sensibit variants, Mucovibrol, Quadriloid, and dermatologicals like Conazol and Mycelvan. The biotech division focuses on monoclonal antibodies, biosimilars, and recombinant proteins for advanced therapies. All prescription products are certified to ISO 9001 quality standards and backed by decades of pharmaceutical expertise.

Differentiator

Problem solved

Functional benefit

Brands

• Analgen: Over-the-counter analgesic brand for pain relief.
• Conazol
• Cicloferon
• REDUSTAT
• Sensibit
• Mucovibrol
• Quadriloid
• Facidex Total
• Candiflux
• L-ombrix

Products and services

• Analgen Over-the-counter analgesic brand for pain relief, sold through pharmacies and retail outlets.
• Conazol Topical antifungal medication for skin fungal infections.
• Cicloferon XTRM Over-the-counter antiviral treatment and immunomodulator.
• Candiflux Antifungal product for vaginal and cutaneous candidiasis; also available as Candiflux Shampoo for fungal scalp conditions.
• Facidex Total OTC gastrointestinal medication for acid-related conditions.
• L-ombrix OTC antiparasitic medication for intestinal parasites.
• Mycelvan OTC topical antifungal product for skin and nail fungal infections.
• REDUSTAT OTC anti-obesity medication for weight management.
• Sensibit Rin OTC nasal decongestant spray for respiratory relief.
• Sensibit D OTC cough and cold medication.
• Sensibit XP OTC extended-release cold medication.
• Sensibit Alergias OTC antihistamine medication for allergy relief.
• Tusigen NF OTC cough suppressant medication.
• Mucovibrol OTC mucolytic and expectorant medication for respiratory conditions.
• INHIBITRON TWIT OTC gastrointestinal protector for gastric and duodenal ulcers.
• NEDENTO OTC oral health product for gingival care.
• PLENAFEM OTC vitamin and nutritional supplement for women's health.
• QUADRILOID OTC topical medication for skin conditions including burns, dermatitis, and eczema.
• DAFLOXEN (OTC) OTC anti-inflammatory analgesic for pain and fever.
• BRONCOMED OTC bronchial and respiratory medication.
• ASA 100 Prescription low-dose aspirin for cardiovascular prevention.
• DAFLOXEN (Rx) Prescription anti-inflammatory analgesic medication.
• DOSCOXEL Prescription chemotherapy agent (docetaxel-based oncology product).
• GARBICAN Prescription systemic antifungal agent.
• ANALGEN 220 / ANALGEN 550 Prescription analgesic anti-inflammatory medications in 220 mg and 550 mg strengths.
• SUPRADOL / SUPRADOL DUET Prescription analgesic and combination analgesic medications.
• Valextra Prescription anti-infective medication.
• Seltaferon Prescription immunomodulator medication.
• Ceftrianol Prescription cephalosporin antibiotic.
• Macrozit Prescription macrolide antibiotic.
• SLENDER-1 Prescription anti-obesity medication.
• REDUSTAT BOOST Prescription anti-obesity supplement.
• LUMINANCE / RADIANCE Prescription hormonal contraceptive medications.
• GLITACAR-1 Prescription antidiabetic medication.
• CODEGREGAN / LODESTAR / LODESTAR DUO / DEGREGAN / THOREVA Prescription cardiovascular medications.
• XARABAN Prescription anticoagulant (rivaroxaban-class).
• PRESONE Prescription corticosteroid medication.
• RAAS Prescription cardiovascular medication affecting the renin-angiotensin-aldosterone system.
• FLEXAR Prescription muscle relaxant medication.
• Quimara / Locoid Prescription dermatological medications, including Locoid topical corticosteroid.
• TRONIUM IV / TRONIUM 40 Prescription proton pump inhibitor in injectable (IV) and oral (40 mg) formulations.
• ESPASMOTEX Prescription antispasmodic medication.
• FOSFONAT / ZOLNIC Prescription bisphosphonate medications for osteoporosis treatment.
• MUCOVIBROL T / MUCOFLUX Prescription mucolytic combined with antibiotic, and prescription expectorant medications.
• EVEREST / Levante / Sensidex / Sensizone Prescription respiratory medications and antihistamine (Sensidex).
• BOLT 36 / CONTINENTAL / GO Prescription urological medications.
• Lombrix Duet / PARAMIX / FLAGENASE 400 Prescription antiparasitic medications.
• Ectaprim F / Evocs III / Zinolox 4G Prescription antibiotic combination and anti-infective medications.
• Biotechnology Products (Biosimilars and Monoclonal Antibodies) Biopharmaceutical medicines including monoclonal antibodies, biosimilars, and recombinant proteins for treating cancer, asthma, rheumatoid arthritis, and autoimmune conditions; also includes recombinant vaccines (seasonal and pandemic influenza, HPV) produced at the Biotec plant.
• mRNA COVID-19 Vaccine (Moderna technology transfer) Domestic manufacturing of Moderna's COVID-19 vaccine and other respiratory mRNA vaccines in Mexico, produced under a five-year technology transfer agreement signed February 2026.
• AstraZeneca COVID-19 Vaccine (Contract Manufacturing) Contract manufacturing of AstraZeneca's COVID-19 vaccine at Liomont's facilities for Mexico's national vaccination strategy.

Quantifiable outcome

• 12,000 liters of cell culture production capacity per year (Biotec plant), enabling 240,000 doses of biotechnological medicines annually
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered flagship/ core, core and minor.

• Modernaflagship/ coreStrategic or Co-development Partner · 10 February 2026Five-year agreement signed in February 2026 between Mexico's Health Ministry, state-owned company Birmex, Liomont, and Moderna for mRNA vaccine manufacturing in Mexico. Moderna will transfer COVID-19 vaccine technology to Liomont, enabling domestic manufacturing of Moderna's COVID-19 vaccine and other respiratory vaccines. The agreement includes joint scientific research on vaccines for diseases including dengue and cancer, with the goal of advancing Mexico's health sovereignty and establishing the country as a scientific powerhouse. Stéphane Bancel, Moderna CEO, stated the collaboration reflects growing vaccine demand in Mexico and will support public health while driving geographic diversification for the company.
• Modernaflagship/ coreStrategic or Co-development PartnerStrategic agreement as part of Mexico's Plan México initiative to enhance mRNA vaccine supply for respiratory diseases. Moderna supplies its respiratory vaccine portfolio and transfers COVID-19 vaccine technology to Liomont, enabling local mRNA vaccine production capacity in Mexico. This partnership is viewed as a significant step toward rebuilding Mexico's domestic pharmaceutical manufacturing capabilities and health sovereignty.
• UNAM (Universidad Nacional Autónoma de México)coreStrategic or Co-development PartnerR&D collaboration with UNAM for the development of biotechnological medications including monoclonal antibodies, biosimilars, and recombinant vaccines. UNAM collaboration provides scientific and academic expertise supporting Liomont's biotech drug development pipeline, which includes products for cancer, asthma, rheumatoid arthritis, and influenza.
• Birmex (Biología Molecular de México)flagship/ coreStrategic or Co-development PartnerMexican state-owned pharmaceutical company and participant in the five-year mRNA vaccine agreement alongside Liomont, Moderna, and Mexico's Health Ministry. Birmex serves as the government counterpart facilitating domestic vaccine manufacturing technology transfer and distribution capabilities.
• AstraZenecacoreStrategic or Co-development PartnerLiomont manufactures the AstraZeneca COVID-19 vaccine for Mexico. The company confirmed it was managing the arrival of active pharmaceutical ingredient (API) raw materials for vaccine production, with its facilities open to supervision by Mexican health authorities. This partnership positioned Liomont as a critical partner in Mexico's COVID-19 vaccination strategy.
• Junior League of MexicominorStrategic or Co-development PartnerLongstanding collaboration with Junior League of Mexico for the administration of the Premio Amanda Rimoch a la Educación Ambiental, an environmental education award for secondary school students. The award stimulates youth participation in environmental sustainability projects, with prize money provided for winning school projects. Liomont's Fundación Liomont co-administers the award with Junior League of Mexico.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Broad incumbents

• Novartis: Global pharma major with significant biologics and biosimilar presence (Sandoz) in Mexico. Competes with Liomont in cardiovascular, oncology, and respiratory therapeutic categories.
• Sanofi: Global pharmaceutical major with established Mexico commercial operations, prescription biologics, vaccines, and OTC franchises. Competes with Liomont across multiple therapeutic areas in the Mexican market.
• AstraZeneca: Global pharma incumbent and current Liomont manufacturing partner (COVID-19 vaccine production). Overlaps with Liomont in respiratory, cardiovascular, and oncology Rx categories in Mexico.
• Pfizer: Global pharma incumbent with a large Mexico presence spanning prescription drugs, vaccines, and biologics. Represents the multinational benchmark Liomont competes against in institutional and retail channels.
• Apotex: Large generic and biosimilar-focused pharmaceutical company with manufacturing and commercial operations relevant to the LatAm market. Comparable to Liomont's generic and biosimilar franchise.

Direct peers

• Genomma Lab Internacional: Leading Mexican OTC pharmaceutical company with a comparable mass-market OTC brand portfolio (analgesics, dermatology, respiratory, weight management) sold through pharmacy chains. Closest direct competitor in Liomont's OTC/Libre Venta business.
• Laboratorios Silanes: 100% Mexican pharmaceutical manufacturer with a comparable prescription and OTC portfolio spanning cardiovascular, metabolic, and infectious disease therapeutic areas. Closely aligned with Liomont in being a domestic multi-therapeutic manufacturer.
• PiSA Farmacéutica: Mexican pharmaceutical group of similar scale with diversified Rx, generic, and hospital injectable portfolios across Mexico and LatAm. Most directly comparable Mexican-domestic competitor with overlapping therapeutic breadth and manufacturing footprint.
• Laboratorios Armstrong: Mexican pharmaceutical manufacturer with a diversified Rx and OTC portfolio, including injectable products sold through pharmacy and institutional channels. Comparable as a domestic Mexican pharma peer.

Emerging players

• Probiomed: Mexican biotech company specializing in biosimilars and recombinant biologicals — directly comparable to Liomont's Biotec division. Smaller in scale but overlaps in biosimilar mAb and recombinant protein manufacturing for the Mexican market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/liomontmx
• YouTubeyoutube.com/user/LiomontOficial
• Facebookfacebook.com/liomont.com.mx
• LinkedInlinkedin.com/company/laboratorios-liomont
• Instagraminstagram.com/liomont

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Liomont